Onco-Innovations Ltd.

Onco-Innovations Ltd.

0.16
USD
-0.01
(-5.54%)
-0.14EPS
32.05MMarket Cap

Total Valuation

USD

As of July 31, 2026, ONCO-INNOVATIONS LTD. carries a market capitalization of 32.05M, placing it among publicly traded companies globally. Its enterprise value stands at 32.16M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap32.05M
Enterprise Value32.16M

Share Statistics

As of July 31, 2026, ONCO-INNOVATIONS LTD. has 68.31M shares outstanding.

Shares Outstanding68.31M

Valuation Ratios

These figures are as of July 31, 2026. The price-to-sales ratio is 416.60, and the price-to-book ratio stands at 15.85.

PS Ratio416.60
PB Ratio15.85
P/TBV Ratio15.85
P/FCF Ratio-9.29
P/OCF Ratio-9.29

Enterprise Valuation

These figures are as of July 31, 2026. The EV/Sales ratio of 496.11 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 32.16M versus a market cap of 32.05M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales496.11

Financial Position

As of July 31, 2026, ONCO-INNOVATIONS LTD. maintains a current ratio of 1.89, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.94, indicating elevated leverage, while an interest coverage ratio of -6,198.65 demonstrates limited ability to service its debt obligations.

Current Ratio1.89
Quick Ratio1.65
Debt / Equity9.94
Debt / EBITDA-0.03
Interest Coverage-6,198.65

Financial Efficiency

Over the twelve months ended July 31, 2026, ONCO-INNOVATIONS LTD. posted a negative return on equity (ROE) of -592.62, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -378.59, reflecting losses generated across the asset base.

Return on Equity (ROE)-592.62
Return on Assets (ROA)-378.59

Stock Price Statistics

USD

As of the close on October 23, 2026, ONCO-INNOVATIONS LTD.'s stock has declined approximately 85.08% over the past 52 weeks.

52-Week Price Change-85.08%
50-Day Moving Average0.39

Income Statement

USD

Over the twelve months ended July 31, 2026, ONCO-INNOVATIONS LTD. generated 64,834.13 in revenue and converted that into -8.19M in net income, yielding earnings per share of -0.14. EBITDA reached -7.44M, while operating income came in at -7.44M.

Revenue64,834.13
Operating Income-7.44M
Pretax Income-8.19M
Net Income-8.19M
EBITDA-7.44M
EBIT-7.44M
Earnings Per Share (EPS)-0.14

Balance Sheet

USD

As of July 31, 2026, ONCO-INNOVATIONS LTD. holds 81,604.48 in cash and equivalents against 200,957.41 in total debt, resulting in a net debt position of 119,352.93. Total book value stands at 2.02M, with working capital of 1.08M providing operational flexibility.

Cash & Cash Equivalents81,604.48
Total Debt200,957.41
Net Debt119,352.93
Equity (Book Value)2.02M
Book Value Per Share0.03
Working Capital1.08M

Cash Flow

USD

ONCO-INNOVATIONS LTD. produced -2.91M in operating cash flow over the twelve months ended July 31, 2026.

Operating Cash Flow-2.91M
Free Cash Flow-2.91M
FCF Per Share-0.05

Margins

These figures cover the twelve months ended July 31, 2026. The operating margin of -11,472.67 and net profit margin of -12,625.19 provide insight into operational efficiency.

Operating Margin-11,472.67
Pretax Margin-12,625.19
Profit Margin-12,625.19
EBITDA Margin-11,472.67

Dividends & Yields

These figures cover the twelve months ended July 31, 2026. Free cash flow yield is negative at -10.76: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -7.23, meaning ONCO-INNOVATIONS LTD. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-7.23
FCF Yield-10.76

Scores

As of July 31, 2026, ONCO-INNOVATIONS LTD. has an Altman Z-Score of 1.99, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.99